Top Tweets for #CheckMate214
#CheckMate214 final overall survival data: Long-term survival benefits of ipi/nivo in #KidneyCancer. @MikeSerzanMD @DanaFarber joins @PBarataMD @caseccc to discuss data demonstrating maintained OS benefit in intermediate- and poor-risk patients with over eight years follow-up, showing 20-30% plateaus on survival curves. #WatchNow > https://t.co/5EBnLM44Tp
#CheckMate214 final overall survival data: Long-term survival benefits of ipi/nivo in #KidneyCancer. @MikeSerzanMD @DanaFarber joins @PBarataMD @caseccc to discuss data demonstrating maintained OS benefit in intermediate- and poor-risk patients with over eight years follow-up, showing 20-30% plateaus on survival curves. #WatchNow > https://t.co/5EBnLM44Tp
#CheckMate214 final overall survival data: Long-term survival benefits of ipi/nivo in #KidneyCancer. @MikeSerzanMD @DanaFarber joins @PBarataMD @caseccc to discuss data demonstrating maintained OS benefit in intermediate- and poor-risk patients with over eight years follow-up, showing 20-30% plateaus on survival curves. #WatchNow > https://t.co/5EBnLM44Tp
@ZakhariaYousef @cityofhope gives #BestofASCO updates in #kidneycancer and #bladdercancer. Excellent overviews of #Checkmate214 ipi-nivo for RCC, #Keynote564 adjuvant pembro for RCC, #EV302 for EV-pembro for bladder, and #NIAGARA ctDNA analysis! Great seeing him in Dallas!
Nivolumab + Ipilimumab vs sunitinib for first-line treatment of advanced #RenalCellCarcinoma: #FinalAnalysis from the phase 3 #CheckMate214 trial. Presentation by @motzermd @MSKCancerCenter. #ASCO25 written coverage by @RKSayyid @USC > https://t.co/i2q2MImdHs @ASCO
🗣️Kidney Cancer Oral Abstracts #ASCO25
👉Abs4505: Dr @motzermd presenting 9⃣yr f/u Nivo/Ipi vs Sunitinib for 1L ccRCC #CheckMate214
ITT (n = 1096)
♦️96 mo PFS rate = (23% vs 9%)
♦️96 mo DOR rate = (48% vs 19%)
♦️108 mo OS rate = (31% vs 20%)
♦️mOS (53mo vs 38mo) (HR 0.71)
INT/POOR risk (n = 847)
♦️96 mo PFS rate = (25% vs 9%)
♦️96 mo PFS rate = (50% vs 23%)
♦️108 mo OS rate = (30% vs 19%)
♦️mOS (47mo vs 26mo) (HR 0.69)
FAV risk (n = 847)
♦️96 mo PFS rate = (13% vs 11%)
♦️96 mo DOR rate = (36% vs NA)
♦️108 mo OS rate = (35% vs 22%)
♦️mOS (78mo vs 67mo) (HR 0.80)
🩺KEY TAKE AWAYS
- Nivo/Ipi a/w long term durable responses in ITT w/plateaus in PFS (23%) and OS (31%) curves and median DOR (76.2mo vs 25.1mo)
- FAV risk OS improved from 1.45 (2018) to 0.80 (2025) suggesting long-term benefit of induction IO regimen
❓ How to we #RaiseTheTail leading to more cures?
Ongoing 1L ccRCC Studies
✨#PEDIGREE Adaptive Sequential Therapy
✨#OPTIC Cluster Selected IO/IO vs IO/TKI
✨#CURE1 PD1 Selected IO/IO vs IO/TKI
✨#ARCITECT novel CTLA #Botensilimab
👥@DrChoueiri @ERPlimackMD @TiansterZhang @DrRanaMcKay @tompowles1 @brian_rini @BraunMDPhD @HHammersMD @PBarataMD @PavlosMsaouel @yekeduz_emre @DrYukselUrun @ReneeSaliby @drenriquegrande @bavilima @DRBakaloudiMD @ReginaBarCar @crisbergerot @kidneycan @KidneyCancer @ASCO
Evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced #RenalCellCarcinoma: Post-hoc analysis of #CheckMate214. Presentation by @VincentWenxinXu @DanaFarber > https://t.co/CwAVHj9GqF @ASCO
🔥 New from #GU25! Dr. Wenxin Xu presents post-hoc #CheckMate214 analysis:
📉 Early KIM-1 drop (3 wks) w/ Nivo+Ipi predicts long-term efficacy
⚠️ High baseline KIM-1 = worse OS/PFS
🔬 Prospective trials needed to confirm KIM-1 as a biomarker for IO response! 🚀
🖋️:@hjwang26
What is KIM-1 (kidney injury molecule) & it’s role as a prognostic/predictive biomarker in RCC? Analysis of KIM-1 in #CheckMate214 of ipi/nivo vs sunitinib @ASCO #GU25
KIM-1 is transmembrane protein over-expressed in ccRCC and emerging biomarker...
Key Takeaways, in CheckMate214:
✅Early decrease in serum KIM-1 at 3w after nivo/ipi is associated with long term efficacy (not sunitinib arm)
📌Higher baseline KIM-1 has worse outcomes in patients and a higher tumor burden
📌Higher KIM-1 associated with worse IMDC risk and no prior nephrectomy
🔎Circulating KIM-1 should be evaluated in prospective trials as early biomarker for response to IO in RCC
@OncoAlert @GUOncologyNow @urotoday @TargetedOnc @OncoReporte @OncLive @kidneycan @KidneyCancer
.@DrJeffreyGraham reviewing 8-year follow-up data and OS rates from #CheckMate214 study of patients with advanced renal-cell carcinoma. Watch his full session here: https://t.co/BVNaEjiwaJ
#KidneyCancer #MedOnc
📅 March is #KidneyCancerAwarenessMonth.
📺 In our latest video, @Daniel_J_George of @DukeCancer, @DukeHealth, shares his expert opinion on the 8-year #CheckMate214 survival and durable response data for advanced #KidneyCancer.
🎥 Watch Now: https://t.co/upsyJybYfw
Nivolumab + ipilimumab vs sunitinib for first-line treatment of advanced #RCC: long-term follow-up data from the phase 3 #CheckMate214 trial. Presented by Nizar Tannir, MD, FACP @MDAndersonNews. #GU24 written coverage by @zklaassen_md @GACancerCenter > https://t.co/6SlLdyaW8V
#NizarTannir & @bmsnews team with true dedication to the study follow-up of #Checkmate214 — 8 year data and moving the needle in favorable risk #kidneycancer. Ipi-nivo should be considered when shooting for durable response and long term survival benefit. @ASCO #GU24 @OncoAlert
4/ #TumorBoardTuesday #BonumCE
#RenalCell #NephTwitter #MedTwitter
Let’s revisit efficacy of 🔑Ph3 clin trials:
💎#CLEAR
💎#KEYNOTE426
💎#CheckMate9ER
💎#CheckMate214
4/ #TumorBoardTuesday #BonumCE
#RenalCell #NephTwitter #MedTwitter
Let’s revisit efficacy of 🔑Ph3 clin trials:
💎#CLEAR
💎#KEYNOTE426
💎#CheckMate9ER
💎#CheckMate214
4/ #TumorBoardTuesday #BonumCE
#RenalCell #NephTwitter #MedTwitter
Let’s revisit efficacy of🔑Ph3 clin trials:
💎#CLEAR
💎#KEYNOTE426
💎#CheckMate9ER
💎#CheckMate214
13/#TumorBoardTuesday #BonumCE #RenalCell
#OncTwitter #NephTwitter #MedTwitter
🔬Common tox in pivotal P3 #CHECKMATE214 trial of dual ICI combo🔬
🔸Fatigue
🔹Pruritus
🔸Diarrhea
🔹Rash
🔸Nausea
6/ #TumorBoardTuesday #BonumCE #OncTwitter #NephTwitter #MedTwitter #RenalCell
✳️Dual ICI combo (ipi + nivo) also approved tx option
💎#CheckMate214 - ipi + nivo vs sunitinib
✅Longest follow-up in frontline RCC (>5 years)
✅OS and PFS favor combo tx in int/poor risk pts
5/#TumorBoardTuesday #RenalCell
🔑Ph3 trls #KEYNOTE426, #CLEAR, #CheckMate9ER, #CheckMate214
💎Each combo regimen ⬆️PFS, OS, & ORR vs sunitinib
💎Axi-avelumab approved but OS data immature
💎Benefit across IMDC risk groups
💎Axi-pembro=longest f/u among approved TKI-ICI in RCC
5/#TumorBoardTuesday #RenalCell
🔑Ph3 trls #KEYNOTE426, #CLEAR, #CheckMate9ER, #CheckMate214
💎Each combo regimen ⬆️PFS, OS, & ORR vs sunitinib
💎Axi-avelumab approved but OS data immature
💎Benefit across IMDC risk groups
💎Axi-pembro=longest f/u among approved TKI-ICI in RCC
Last Seen Hashtags on Sotwe
Herkesiçinbarış
Seen from United States
DetoxTank
polynesian
Seen from Australia
dickflash
Seen from Turkey
pawg
Seen from Turkey
gasmask
Seen from United Kingdom
omegle
Seen from Indonesia
nylons
Seen from Turkey
خمسيني_ابها
Seen from Saudi Arabia
momson()()()()()()()()()()()()()()()()()() +filter:native_video
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
240.9M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Cristiano Ronaldo
@cristiano
111.5M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
97.9M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.1M followers
KATY PERRY
@katyperry
88.2M followers
Taylor Swift
@taylorswift13
82M followers
Lady Gaga
@ladygaga
73.5M followers
Virat Kohli
@imvkohli
70.7M followers
Kim Kardashian
@kimkardashian
70M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64.2M followers
Neymar Jr
@neymarjr
63.5M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.9M followers
Selena Gomez
@selenagomez
61.2M followers
X
@x
60.8M followers